Assessing blood tests for lung transplant rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the relationship between donor-derived cell-free DNA (dd-cfDNA) levels and HLA antibodies in lung transplant recipients. It seeks to evaluate the effectiveness of the Molecular Microscope® Diagnostic System (MMDx) in analyzing biopsy samples and blood tests to improve the accuracy of rejection assessments. By comparing traditional biopsy methods with new blood tests, the study hopes to enhance patient safety and diagnostic precision in lung transplantation. The research will involve multiple institutions to gather comprehensive data on lung transplant outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adult, Older adult

Exclusion Criteria:

Patients will be excluded from the study if they decline participation Are unable to give informed consent. Recipients of multiple organs, cancer patients and pregnant women

Where it's running

• St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT
  Phoenix, Arizona, United States Recruiting
• Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, College of Medicine
  Gainesville, Florida, United States Recruiting
• Mayo Clinic Florida, 4500 San Pablo Rd
  Jacksonville, Florida, United States Recruiting
• Indiana University Methodist Hospital 1812 N. Capitol Ave Suite W131L
  Indianapolis, Indiana, United States Recruiting
• Johns Hopkins Interventional Pulmonology, Sheikh Zayed Tower, Room 7125L, 1800 Orleans Street
  Baltimore, Maryland, United States Recruiting
• Division of Pulmonary, Allergy & Critical Care Medicine Columbia University Irving Medical Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Philip F Halloran, MD PhD — Alberta Transplant Applied Genomics Centre, University of Alberta
• Study coordinator: Konrad S Famulski, PhD DSc
• Email: konrad@ualberta.ca
• Phone: 1 780 782 9463

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Muscle health before and after lung transplant in adults

  This study tests how respiratory and leg muscle health relates to physical function and recovery in adults awaiting and after lung transplantation.

  Recruiting University of Florida · Gainesville, Florida · NCT07747337

• Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency

  This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.

  Recruiting at 4 sites University Hospital, Bordeaux · Bron and 3 other locations · NCT07715617

• Long-term health of children born to mothers who had a solid organ transplant

  This project will look for long-term heart, kidney, and immune system problems in people aged 16 and older who were born to mothers who had a kidney, liver, pancreas, heart, or lung transplant.

  Recruiting University Medical Center Groningen · Groningen, Provincie Groningen · NCT07291258

• Aerobic versus high-intensity interval exercise for people awaiting lung transplant

  This trial tests whether short bursts of high-intensity interval training or longer moderate aerobic sessions better improve walking distance and daily function for people with interstitial lung disease who are on the lung transplant waiting list.

  Recruiting Ankara City Hospital Bilkent · Ankara · NCT07065318

• Tacrolimus Melt-Dose® for people after a lung transplant

  This study will test how a once-daily Melt-Dose® tacrolimus (LCPT) is processed in the body and how safe it is for adults who recently had a unilateral or bilateral lung transplant over 12 months.

  Recruiting at 2 sites Chiesi España, S.A.U. · L'Hospitalet de Llobregat, Barcelona and 1 other locations · NCT07042035

• Fostamatinib to see if it’s safe for lung transplant patients with donor-specific antibodies

  This trial tests whether taking fostamatinib is safe for adults who have donor-specific antibodies after a lung transplant.

  Recruiting at 4 sites Phase 1 National Institutes of Health Clinical Center (CC) · Stanford, California and 3 other locations · NCT06948097

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.